Skip to content
Sign inOpen the app
Artwork for On The Pen GLP-1 News
On The Pen GLP-1 News · April 14 · 20 min

Foundayo GLP-1 Pill: FDA Needs More Data

Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use. Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.

0:00-20:24
Play in podnod

transcript

No transcript — this publisher did not publish one.

show notes

Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use.

Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.

more episodes

All episodes